Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke

This study investigated the neuroprotective potential of delta sleep-inducing peptide (DSIP) in a focal ischemic stroke model in Sprague-Dawley rats. Researchers induced cerebral ischemia via middle cerebral artery occlusion and administered DSIP intranasally at a dose of 120 µg/kg at different time windows after the ischemic event.

Results demonstrated that DSIP-treated animals showed significantly faster recovery of motor functions compared to the control group. Neurological assessment included grip strength, balance, and motor coordination tests, in which the treated group consistently outperformed the placebo group throughout the follow-up period.

An interesting aspect of the study is the choice of the intranasal route, which allows the peptide to bypass the blood-brain barrier and directly reach the central nervous system. This administration route is particularly relevant for future clinical applications, as it is non-invasive and easy to administer.

The authors concluded that DSIP possesses promising neuroprotective properties in cerebral ischemia settings, possibly mediated by antioxidant and anti-apoptotic mechanisms. These findings open perspectives for future investigations into the use of DSIP as an adjuvant therapeutic agent in the management of ischemic stroke.